Pimasertib-associated ophthalmological adverse events.

Elon H C Van DijkWim H J KruitMartine J JagerGregorius P M LuytenJohannes R VingerlingCamiel J F Boon

Published in: Acta ophthalmologica (2018)

Patients with metastatic CM who are treated with the MEK inhibitor pimasertib are at high risk of development of ocular adverse events including serous retinopathy and possibly RVO, stressing the need of adequate ophthalmological follow-up including OCT during administration of pimasertib, despite the fact that SRF generally does not lead to ophthalmological complaints.

Keyphrases

high grade
optic nerve
optical coherence tomography
diabetic retinopathy
signaling pathway